132 related articles for article (PubMed ID: 38671582)
1. Near-infrared photoimmunotherapy targeting PD-L1: Improved efficacy by preconditioning the tumor microenvironment.
Inagaki FF; Kano M; Furusawa A; Kato T; Okada R; Fukushima H; Takao S; Okuyama S; Choyke PL; Kobayashi H
Cancer Sci; 2024 Apr; ():. PubMed ID: 38671582
[TBL] [Abstract][Full Text] [Related]
2. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity.
Taki S; Matsuoka K; Nishinaga Y; Takahashi K; Yasui H; Koike C; Shimizu M; Sato M; Sato K
J Immunother Cancer; 2021 Oct; 9(11):. PubMed ID: 34725216
[TBL] [Abstract][Full Text] [Related]
3. Near-Infrared Photoimmunotherapy of Cancer.
Kobayashi H; Choyke PL
Acc Chem Res; 2019 Aug; 52(8):2332-2339. PubMed ID: 31335117
[TBL] [Abstract][Full Text] [Related]
4. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
[TBL] [Abstract][Full Text] [Related]
5. Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials.
Okada R; Furusawa A; Vermeer DW; Inagaki F; Wakiyama H; Kato T; Nagaya T; Choyke PL; Spanos WC; Allen CT; Kobayashi H
EBioMedicine; 2021 May; 67():103345. PubMed ID: 33933782
[TBL] [Abstract][Full Text] [Related]
6. Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models.
Maruoka Y; Furusawa A; Okada R; Inagaki F; Fujimura D; Wakiyama H; Kato T; Nagaya T; Choyke PL; Kobayashi H
Vaccines (Basel); 2020 Sep; 8(3):. PubMed ID: 32937841
[TBL] [Abstract][Full Text] [Related]
7. Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers.
Wakiyama H; Furusawa A; Okada R; Inagaki F; Kato T; Furumoto H; Fukushima H; Okuyama S; Choyke PL; Kobayashi H
Cancer Immunol Immunother; 2022 Dec; 71(12):2869-2879. PubMed ID: 35445836
[TBL] [Abstract][Full Text] [Related]
8. [Near Infrared Photoimmunotherapy for Cancer].
Kobayashi H
Gan To Kagaku Ryoho; 2019 Jan; 46(1):28-33. PubMed ID: 30765637
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy.
Okada R; Maruoka Y; Furusawa A; Inagaki F; Nagaya T; Fujimura D; Choyke PL; Kobayashi H
Bioconjug Chem; 2019 Oct; 30(10):2624-2633. PubMed ID: 31498995
[TBL] [Abstract][Full Text] [Related]
10. Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.
Nagaya T; Friedman J; Maruoka Y; Ogata F; Okuyama S; Clavijo PE; Choyke PL; Allen C; Kobayashi H
Cancer Immunol Res; 2019 Mar; 7(3):401-413. PubMed ID: 30683733
[TBL] [Abstract][Full Text] [Related]
11. [Novel Therapy Targeting the Cancer Microenvironment Using Near-Infrared Photoimmunotherapy Leading to Tumor Immune Activation].
Kato T; Noma K; Furusawa A; Kobayashi H; Fujiwara T
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1361-1363. PubMed ID: 38303275
[TBL] [Abstract][Full Text] [Related]
12. Increased Immunogenicity of a Minimally Immunogenic Tumor after Cancer-Targeting Near Infrared Photoimmunotherapy.
Wakiyama H; Furusawa A; Okada R; Inagaki F; Kato T; Maruoka Y; Choyke PL; Kobayashi H
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322807
[TBL] [Abstract][Full Text] [Related]
13. CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model.
Furusawa A; Okada R; Inagaki F; Wakiyama H; Kato T; Furumoto H; Fukushima H; Okuyama S; Choyke PL; Kobayashi H
Oncoimmunology; 2022; 11(1):2019922. PubMed ID: 35003897
[TBL] [Abstract][Full Text] [Related]
14. Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT).
Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Kobayashi H
J Control Release; 2016 Jun; 232():1-8. PubMed ID: 27059723
[TBL] [Abstract][Full Text] [Related]
15. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer.
Yamashita S; Kojima M; Onda N; Yoshida T; Shibutani M
Cancer Med; 2023 Feb; 12(4):4579-4589. PubMed ID: 36259134
[TBL] [Abstract][Full Text] [Related]
17. Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen.
Nagaya T; Sato K; Harada T; Nakamura Y; Choyke PL; Kobayashi H
PLoS One; 2015; 10(8):e0136829. PubMed ID: 26313651
[TBL] [Abstract][Full Text] [Related]
18. Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer.
Harada T; Nakamura Y; Sato K; Nagaya T; Okuyama S; Ogata F; Choyke PL; Kobayashi H
Oncotarget; 2016 Nov; 7(48):79408-79416. PubMed ID: 27765903
[TBL] [Abstract][Full Text] [Related]
19. Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response.
Kato T; Fukushima H; Furusawa A; Okada R; Wakiyama H; Furumoto H; Okuyama S; Takao S; Choyke PL; Kobayashi H
Oncoimmunology; 2022; 11(1):2152248. PubMed ID: 36465486
[TBL] [Abstract][Full Text] [Related]
20. Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy.
Okada R; Kato T; Furusawa A; Inagaki F; Wakiyama H; Fujimura D; Okuyama S; Furumoto H; Fukushima H; Choyke PL; Kobayashi H
Cancer Immunol Immunother; 2022 Aug; 71(8):1877-1887. PubMed ID: 35013765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
